Perspective Therapeutics, Inc. Updates Corporate Presentation

SEC Filing 8-K (0000950170-25-101414)

On August 1, 2025, Perspective Therapeutics, Inc. filed a Form 8-K to report the update of its corporate presentation. The updated presentation, which is filed as Exhibit 99.1, highlights the company's innovative radiopharmaceutical platform aimed at revolutionizing oncology treatment. The platform focuses on higher potency payloads with cancer-specific targeting, optimized for a broader therapeutic window. The presentation also details the company's ongoing clinical trials, including Phase 1/2a trials for neuroendocrine tumors and metastatic melanoma, and discusses the proposed mechanism of action for 212Pb and its synergy with immune checkpoint inhibitors. Additionally, the company emphasizes its supply chain and manufacturing infrastructure, ensuring on-demand order fulfillment at regional sites.